Drug Status in USA : Approved Drug Status in Canada : Approved
Indication : Why is this medication prescribed?
Atrial and ventricular arhythmias. Maintenance of sinus rhythm following electro conversion. II line of drug for uncomplicated plasmodium falciparum malaria.
Contraindication: What are the special precautions to be followed?
Under following conditions, use of this medication is inadvisable. Its use should be withhold as it would cause harm to the patient Hypersensitivity. Myasthenia gravis. Complete heart block, digitalis intoxication, hypotension and CHF.
Other Precaution to be observed while taking this medication
Atrial flutter, widening QRS complex, incomplete AV block, uncompensated heart failure, acute infections, fever, digitalised patients, hypokalaemia, acute MI, renal or hepatic impairment, elderly. Prolonged QT interval. Pregnancy and lactation.
What are possible side effects of this medication ?
Higher doses can cause A.V. dissociation, nausea, vomiting, diarhhoea, cinchonism (ringing in ear, deafness vertigo, headache, visual disturbance) angioedema, asthma and vascular collapse. Fibrillation. Thrombocytopenia. Exfoliative. Torsads De Pointes.
Drug Category/Class
Anti-Arrhythmia Agents
Muscarinic Antagonists
Voltage-Gated Sodium Channel Blockers
Adrenergic alpha-Antagonists
Cardiovascular System
Antiarrhythmics, Class I and Iii
Cardiac Therapy
Antiarrythmics, Class I and Iii
Antiarrhythmics, Class Ia
BSEP
ABCB11 Inhibitors
Antimalarials
CYP2E1 Inhibitors
CYP2E1 Inducers
CYP2E1 Inducers (strong)
Combined Inhibitors of CYP3A4 and
Prescribed
For the treatment of ventricular pre-excitation and cardiac dysrhythmias